Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761.

Fu,Y., Ponce,M.L., Thill,M., Yuan,P., Wang,N.S., and Csaky,K.G. 2007. Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol. Vis. Sci. 48, 5184-5190.